243 related articles for article (PubMed ID: 29054568)
21. Causality and functional relevance of BRCA1 and BRCA2 pathogenic variants in non-high-grade serous ovarian carcinomas.
Kramer C; Lanjouw L; Ruano D; Ter Elst A; Santandrea G; Solleveld-Westerink N; Werner N; van der Hout AH; de Kroon CD; van Wezel T; Berger L; Jalving M; Wesseling J; Smit V; de Bock GH; van Asperen CJ; Mourits M; Vreeswijk M; Bart J; Bosse T
J Pathol; 2024 Feb; 262(2):137-146. PubMed ID: 37850614
[TBL] [Abstract][Full Text] [Related]
22. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
Pharoah PD; Palmieri RT; Ramus SJ; Gayther SA; Andrulis IL; Anton-Culver H; Antonenkova N; Antoniou AC; Goldgar D; ; Beattie MS; Beckmann MW; Birrer MJ; Bogdanova N; Bolton KL; Brewster W; Brooks-Wilson A; Brown R; Butzow R; Caldes T; Caligo MA; Campbell I; Chang-Claude J; Chen YA; Cook LS; Couch FJ; Cramer DW; Cunningham JM; Despierre E; Doherty JA; Dörk T; Dürst M; Eccles DM; Ekici AB; Easton D; ; Fasching PA; de Fazio A; Fenstermacher DA; Flanagan JM; Fridley BL; Friedman E; Gao B; Sinilnikova O; ; Gentry-Maharaj A; Godwin AK; Goode EL; Goodman MT; Gross J; Hansen TV; Harnett P; Rookus M; ; Heikkinen T; Hein R; Høgdall C; Høgdall E; Iversen ES; Jakubowska A; Johnatty SE; Karlan BY; Kauff ND; Kaye SB; Chenevix-Trench G; ; Kelemen LE; Kiemeney LA; Kjaer SK; Lambrechts D; Lapolla JP; Lázaro C; Le ND; Leminen A; Leunen K; Levine DA; Lu Y; Lundvall L; Macgregor S; Marees T; Massuger LF; McLaughlin JR; Menon U; Montagna M; Moysich KB; Narod SA; Nathanson KL; Nedergaard L; Ness RB; Nevanlinna H; Nickels S; Osorio A; Paul J; Pearce CL; Phelan CM; Pike MC; Radice P; Rossing MA; Schildkraut JM; Sellers TA; Singer CF; Song H; Stram DO; Sutphen R; Lindblom A; ; Terry KL; Tsai YY; van Altena AM; Vergote I; Vierkant RA; Vitonis AF; Walsh C; Wang-Gohrke S; Wappenschmidt B; Wu AH; Ziogas A; Berchuck A; Risch HA;
Clin Cancer Res; 2011 Jun; 17(11):3742-50. PubMed ID: 21385923
[TBL] [Abstract][Full Text] [Related]
23. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk.
Amankwah EK; Lin HY; Tyrer JP; Lawrenson K; Dennis J; Chornokur G; Aben KK; Anton-Culver H; Antonenkova N; Bruinsma F; Bandera EV; Bean YT; Beckmann MW; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bunker CH; Butzow R; Campbell IG; Carty K; Chen Z; Chen YA; Chang-Claude J; Cook LS; Cramer DW; Cunningham JM; Cybulski C; Dansonka-Mieszkowska A; du Bois A; Despierre E; Dicks E; Doherty JA; Dörk T; Dürst M; Easton DF; Eccles DM; Edwards RP; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Goodman MT; Gronwald J; Harrington P; Harter P; Hasmad HN; Hein A; Heitz F; Hildebrandt MA; Hillemanns P; Hogdall CK; Hogdall E; Hosono S; Iversen ES; Jakubowska A; Jensen A; Ji BT; Karlan BY; Jim H; Kellar M; Kiemeney LA; Krakstad C; Kjaer SK; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lim BK; Lissowska J; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; McNeish I; Menon U; Milne RL; Modugno F; Moysich KB; Ness RB; Nevanlinna H; Eilber U; Odunsi K; Olson SH; Orlow I; Orsulic S; Weber RP; Paul J; Pearce CL; Pejovic T; Pelttari LM; Permuth-Wey J; Pike MC; Poole EM; Risch HA; Rosen B; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schernhammer E; Schwaab I; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Spiewankiewicz B; Sucheston-Campbell L; Teo SH; Terry KL; Thompson PJ; Thomsen L; Tangen IL; Tworoger SS; van Altena AM; Vierkant RA; Vergote I; Walsh CS; Wang-Gohrke S; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Wu AH; Wu X; Woo YL; Yang H; Zheng W; Ziogas A; Kelemen LE; Berchuck A; ; Schildkraut JM; Ramus SJ; Goode EL; Monteiro AN; Gayther SA; Narod SA; Pharoah PD; Sellers TA; Phelan CM
Genet Epidemiol; 2015 Dec; 39(8):689-97. PubMed ID: 26399219
[TBL] [Abstract][Full Text] [Related]
24. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.
Hampras SS; Sucheston-Campbell LE; Cannioto R; Chang-Claude J; Modugno F; Dörk T; Hillemanns P; Preus L; Knutson KL; Wallace PK; Hong CC; Friel G; Davis W; Nesline M; Pearce CL; Kelemen LE; Goodman MT; Bandera EV; Terry KL; Schoof N; Eng KH; Clay A; Singh PK; Joseph JM; Aben KK; Anton-Culver H; Antonenkova N; Baker H; Bean Y; Beckmann MW; Bisogna M; Bjorge L; Bogdanova N; Brinton LA; Brooks-Wilson A; Bruinsma F; Butzow R; Campbell IG; Carty K; Cook LS; Cramer DW; Cybulski C; Dansonka-Mieszkowska A; Dennis J; Despierre E; Dicks E; Doherty JA; du Bois A; Dürst M; Easton D; Eccles D; Edwards RP; Ekici AB; Fasching PA; Fridley BL; Gao YT; Gentry-Maharaj A; Giles GG; Glasspool R; Gronwald J; Harrington P; Harter P; Hasmad HN; Hein A; Heitz F; Hildebrandt MA; Hogdall C; Hogdall E; Hosono S; Iversen ES; Jakubowska A; Jensen A; Ji BT; Karlan BY; Kellar M; Kelley JL; Kiemeney LA; Klapdor R; Kolomeyevskaya N; Krakstad C; Kjaer SK; Kruszka B; Kupryjanczyk J; Lambrechts D; Lambrechts S; Le ND; Lee AW; Lele S; Leminen A; Lester J; Levine DA; Liang D; Lissowska J; Liu S; Lu K; Lubinski J; Lundvall L; Massuger LF; Matsuo K; McGuire V; McLaughlin JR; McNeish I; Menon U; Moes-Sosnowska J; Narod SA; Nedergaard L; Nevanlinna H; Nickels S; Olson SH; Orlow I; Weber RP; Paul J; Pejovic T; Pelttari LM; Perkins B; Permuth-Wey J; Pike MC; Plisiecka-Halasa J; Poole EM; Risch HA; Rossing MA; Rothstein JH; Rudolph A; Runnebaum IB; Rzepecka IK; Salvesen HB; Schernhammer E; Schmitt K; Schwaab I; Shu XO; Shvetsov YB; Siddiqui N; Sieh W; Song H; Southey MC; Tangen IL; Teo SH; Thompson PJ; Timorek A; Tsai YY; Tworoger SS; Tyrer J; van Altena AM; Vergote I; Vierkant RA; Walsh C; Wang-Gohrke S; Wentzensen N; Whittemore AS; Wicklund KG; Wilkens LR; Wu AH; Wu X; Woo YL; Yang H; Zheng W; Ziogas A; Gayther SA; Ramus SJ; Sellers TA; Schildkraut JM; Phelan CM; Berchuck A; Chenevix-Trench G; Cunningham JM; Pharoah PP; Ness RB; Odunsi K; Goode EL; Moysich KB
Oncotarget; 2016 Oct; 7(43):69097-69110. PubMed ID: 27533245
[TBL] [Abstract][Full Text] [Related]
25. Epithelial ovarian cancer risk: A review of the current genetic landscape.
Flaum N; Crosbie EJ; Edmondson RJ; Smith MJ; Evans DG
Clin Genet; 2020 Jan; 97(1):54-63. PubMed ID: 31099061
[TBL] [Abstract][Full Text] [Related]
26. A targeted genetic association study of epithelial ovarian cancer susceptibility.
Earp M; Winham SJ; Larson N; Permuth JB; Sicotte H; Chien J; Anton-Culver H; Bandera EV; Berchuck A; Cook LS; Cramer D; Doherty JA; Goodman MT; Levine DA; Monteiro AN; Ness RB; Pearce CL; Rossing MA; Tworoger SS; Wentzensen N; Bisogna M; Brinton L; Brooks-Wilson A; Carney ME; Cunningham JM; Edwards RP; Fogarty ZC; Iversen ES; Kraft P; Larson MC; Le ND; Lin HY; Lissowska J; Modugno F; Moysich KB; Olson SH; Pike MC; Poole EM; Rider DN; Terry KL; Thompson PJ; van den Berg D; Vierkant RA; Vitonis AF; Wilkens LR; Wu AH; Yang HP; Ziogas A; Phelan CM; Schildkraut JM; Chen YA; Sellers TA; Fridley BL; Goode EL
Oncotarget; 2016 Feb; 7(7):7381-9. PubMed ID: 26848776
[TBL] [Abstract][Full Text] [Related]
27. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.
DeVries AA; Dennis J; Tyrer JP; Peng PC; Coetzee SG; Reyes AL; Plummer JT; Davis BD; Chen SS; Dezem FS; Aben KKH; Anton-Culver H; Antonenkova NN; Beckmann MW; Beeghly-Fadiel A; Berchuck A; Bogdanova NV; Bogdanova-Markov N; Brenton JD; Butzow R; Campbell I; Chang-Claude J; Chenevix-Trench G; Cook LS; DeFazio A; Doherty JA; Dörk T; Eccles DM; Eliassen AH; Fasching PA; Fortner RT; Giles GG; Goode EL; Goodman MT; Gronwald J; ; ; Håkansson N; Hildebrandt MAT; Huff C; Huntsman DG; Jensen A; Kar S; Karlan BY; Khusnutdinova EK; Kiemeney LA; Kjaer SK; Kupryjanczyk J; Labrie M; Lambrechts D; Le ND; Lubiński J; May T; Menon U; Milne RL; Modugno F; Monteiro AN; Moysich KB; Odunsi K; Olsson H; Pearce CL; Pejovic T; Ramus SJ; Riboli E; Riggan MJ; Romieu I; Sandler DP; Schildkraut JM; Setiawan VW; Sieh W; Song H; Sutphen R; Terry KL; Thompson PJ; Titus L; Tworoger SS; Van Nieuwenhuysen E; Edwards DV; Webb PM; Wentzensen N; Whittemore AS; Wolk A; Wu AH; Ziogas A; Freedman ML; Lawrenson K; Pharoah PDP; Easton DF; Gayther SA; Jones MR
J Natl Cancer Inst; 2022 Nov; 114(11):1533-1544. PubMed ID: 36210504
[TBL] [Abstract][Full Text] [Related]
28. Common Genetic Variation and Susceptibility to Ovarian Cancer: Current Insights and Future Directions.
Kar SP; Berchuck A; Gayther SA; Goode EL; Moysich KB; Pearce CL; Ramus SJ; Schildkraut JM; Sellers TA; Pharoah PDP
Cancer Epidemiol Biomarkers Prev; 2018 Apr; 27(4):395-404. PubMed ID: 28615364
[TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.
Cunningham JM; Cicek MS; Larson NB; Davila J; Wang C; Larson MC; Song H; Dicks EM; Harrington P; Wick M; Winterhoff BJ; Hamidi H; Konecny GE; Chien J; Bibikova M; Fan JB; Kalli KR; Lindor NM; Fridley BL; Pharoah PP; Goode EL
Sci Rep; 2014 Feb; 4():4026. PubMed ID: 24504028
[TBL] [Abstract][Full Text] [Related]
30. Biology of epithelial ovarian cancer: implications for screening women at high genetic risk.
Hogg R; Friedlander M
J Clin Oncol; 2004 Apr; 22(7):1315-27. PubMed ID: 15051780
[TBL] [Abstract][Full Text] [Related]
31. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
32. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma.
Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
[TBL] [Abstract][Full Text] [Related]
33. Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants.
Jervis S; Song H; Lee A; Dicks E; Tyrer J; Harrington P; Easton DF; Jacobs IJ; Pharoah PP; Antoniou AC
J Med Genet; 2014 Feb; 51(2):108-13. PubMed ID: 24277755
[TBL] [Abstract][Full Text] [Related]
34. New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study.
Plaskocinska I; Shipman H; Drummond J; Thompson E; Buchanan V; Newcombe B; Hodgkin C; Barter E; Ridley P; Ng R; Miller S; Dann A; Licence V; Webb H; Tan LT; Daly M; Ayers S; Rufford B; Earl H; Parkinson C; Duncan T; Jimenez-Linan M; Sagoo GS; Abbs S; Hulbert-Williams N; Pharoah P; Crawford R; Brenton JD; Tischkowitz M
J Med Genet; 2016 Oct; 53(10):655-61. PubMed ID: 27208206
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetics and epidemiology of epithelial ovarian cancer (Review).
Haruta S; Furukawa N; Yoshizawa Y; Tsunemi T; Nagai A; Kawaguchi R; Tanase Y; Yoshida S; Kobayashi H
Oncol Rep; 2011 Dec; 26(6):1347-56. PubMed ID: 21922146
[TBL] [Abstract][Full Text] [Related]
36. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
38. Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.
Mackenzie R; Talhouk A; Eshragh S; Lau S; Cheung D; Chow C; Le N; Cook LS; Wilkinson N; McDermott J; Singh N; Kommoss F; Pfisterer J; Huntsman DG; Köbel M; Kommoss S; Gilks CB; Anglesio MS
Am J Surg Pathol; 2015 Nov; 39(11):1548-57. PubMed ID: 26099008
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women.
Manchanda R; Patel S; Gordeev VS; Antoniou AC; Smith S; Lee A; Hopper JL; MacInnis RJ; Turnbull C; Ramus SJ; Gayther SA; Pharoah PDP; Menon U; Jacobs I; Legood R
J Natl Cancer Inst; 2018 Jul; 110(7):714-725. PubMed ID: 29361001
[TBL] [Abstract][Full Text] [Related]
40. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer.
Ramalingam P
Oncology (Williston Park); 2016 Feb; 30(2):166-76. PubMed ID: 26892153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
